
Skin & Soft Tissue Diseases
Latest News
Latest Videos

More News

Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.

Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.

The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.

In Response to African Mpox Outbreak, Vaccine is Being Made Available
The vaccine, Jynneos, manufactured by Bavarian Nordic, is being shipped to Africa to address the ongoing mpox outbreak.

Africa CDC Director General: Mpox Outbreak a Public Health Emergency of Continental Security
This is the very first such declaration by the Africa CDC since its inception in 2017.

In part 2 of this interview with Deborah Birx, MD, she highlights that ActivePure Technology provides a continuous decontamination solution that operates independently of manual intervention to reduce HAIs.

Part 1, Deborah Birx, MD explains photohydrolysis technology provides continuous, automated disinfection of air and surfaces effective in controlling MRSA and improving infection control practices in healthcare settings.

A large Veterans Health Administration (VA) outpatient study showed a large increase in MRSA resistance in one particular area of the United States and varying antimicrobial resistance patterns overall.

There is a high potential for ActivePure Medical’s technology to enhance patient safety and reduce healthcare costs by minimizing harmful pathogens in complex healthcare environments.

The prevalence of methicillin-resistant Staphylococcus aureus has surged from 2.58% to 14.79%, highlighting a need for updated treatment strategies.

A study finds clinically-relevant sub-phenotypes can be reproducibly, and could lead to patient stratification and treatment.

A recent report from the CDC highlights how the COVID-19 pandemic has heightened antimicrobial resistance, resulting in a 20% increase in hospital-onset infections caused by key resistant pathogens.

Proposed alternative to "unsustainable" wide use of broad spectrum antibiotic prophylaxis in surgeries confronts antimicrobial resistance.

In the last segment of the series, Jones offered his insights for when he considers discharging patients.

In this conversation, Jones discussed concerns around empirical antimicrobial treatment and opportunities to narrow down therapies.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.

Here is a review of therapies for treating this bacterium.

Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).

Empirical antibiotic therapy in diabetic foot ulcer infections increases hospitalization and prolonged symptoms in patients being treated for lower limb cellulitis are common. Two recent papers examine the need for effective communication, the importance of objective findings in cellulitis management, and the benefits of culture-based antibiotic therapy in diabetic foot ulcer cases.

George Sakoulas, MD, shares key takeaways on soft tissue infections from ID week 2023.

Dr George Sakoulas provides insight on how single-dose agents fit into antimicrobial stewardship for soft tissue infections.

George Sakoulas, MD, provides key insights on the management of soft tissue infections including the role of single-dose agents and treating patients in an outpatient setting.

A comparative study found that using linezolid in place of clindamycin in combination with vancomycin for the treatment of necrotizing soft tissue infections resulted in similar 30-day mortality rates but lower rates of acute kidney injury and composite adverse outcomes, suggesting the effectiveness and safety of linezolid as an alternative therapy.

The federal agency gave the nod to Verrica Pharmaceuticals for its therapy, VP-102 (Ycanthe), for molluscum contagiosum (molluscum), making it the first treatment indicated for the viral-borne skin disease.



















































































































































































